EcoR1 Capital as of Dec. 31, 2018
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 53 positions in its portfolio as reported in the December 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Argenx Se (ARGX) | 7.9 | $79M | 825k | 96.07 | |
Kura Oncology (KURA) | 7.4 | $74M | 5.3M | 14.04 | |
Fibrogen (FGEN) | 7.1 | $71M | 1.5M | 46.28 | |
Ironwood Pharmaceuticals (IRWD) | 5.6 | $56M | 5.4M | 10.36 | |
Assembly Biosciences | 5.4 | $54M | 2.4M | 22.62 | |
Spark Therapeutics | 4.5 | $45M | 1.1M | 39.14 | |
Ascendis Pharma A S (ASND) | 4.3 | $43M | 680k | 62.65 | |
Ionis Pharmaceuticals (IONS) | 3.9 | $39M | 725k | 54.06 | |
Fibrogen | 3.9 | $39M | 841k | 46.28 | |
Xencor (XNCR) | 3.6 | $36M | 989k | 36.16 | |
Dicerna Pharmaceuticals | 3.5 | $36M | 3.3M | 10.69 | |
Scholar Rock Hldg Corp (SRRK) | 3.4 | $34M | 1.5M | 22.97 | |
Mirati Therapeutics | 2.8 | $28M | 647k | 42.42 | |
Kezar Life Sciences | 2.5 | $25M | 1.1M | 23.60 | |
Solid Biosciences | 2.3 | $23M | 867k | 26.80 | |
Ascendis Pharma A S put | 2.3 | $23M | 360k | 62.65 | |
Akcea Therapeutics Inc equities | 1.9 | $19M | 640k | 30.14 | |
Gilead Sciences Inc option | 1.8 | $18M | 285k | 62.55 | |
Eiger Biopharmaceuticals | 1.6 | $16M | 1.6M | 10.16 | |
Unity Biotechnology | 1.6 | $16M | 967k | 16.26 | |
Ascendis Pharma A S call | 1.6 | $16M | 250k | 62.65 | |
Sangamo Biosciences (SGMO) | 1.4 | $14M | 1.2M | 11.48 | |
Zai Lab (ZLAB) | 1.3 | $13M | 569k | 23.22 | |
Arcus Biosciences Incorporated (RCUS) | 1.3 | $13M | 1.2M | 10.77 | |
Arbutus Biopharma (ABUS) | 1.3 | $13M | 3.3M | 3.83 | |
Celgene Corp option | 1.2 | $13M | 195k | 64.09 | |
Ironwood Pharmaceuticals Inc cl a | 1.2 | $12M | 1.2M | 10.36 | |
Myokardia | 1.1 | $12M | 234k | 48.86 | |
Rhythm Pharmaceuticals (RYTM) | 1.1 | $11M | 401k | 26.88 | |
Nektar Therapeutics | 1.0 | $10M | 317k | 32.87 | |
Wave Life Sciences (WVE) | 1.0 | $9.8M | 234k | 42.04 | |
Surface Oncology | 1.0 | $9.6M | 2.3M | 4.24 | |
Rubius Therapeutics | 0.9 | $9.5M | 592k | 16.08 | |
Array BioPharma | 0.9 | $9.2M | 644k | 14.25 | |
Prothena (PRTA) | 0.9 | $8.6M | 838k | 10.30 | |
Magenta Therapeutics | 0.8 | $7.9M | 1.4M | 5.70 | |
Immune Design | 0.7 | $7.3M | 5.6M | 1.30 | |
Rocket Pharmaceuticals (RCKT) | 0.7 | $6.7M | 450k | 14.82 | |
Crispr Therapeutics (CRSP) | 0.6 | $6.0M | 209k | 28.57 | |
Aquinox Pharmaceuticals | 0.5 | $4.9M | 2.3M | 2.16 | |
Portola Pharmaceuticals | 0.5 | $4.8M | 248k | 19.52 | |
Aclaris Therapeutics (ACRS) | 0.5 | $4.5M | 614k | 7.39 | |
Five Prime Therapeutics | 0.3 | $3.0M | 327k | 9.30 | |
Corcept Therapeutics Incorporated (CORT) | 0.2 | $2.2M | 166k | 13.36 | |
Curis | 0.2 | $2.1M | 3.0M | 0.69 | |
Dynavax Technologies (DVAX) | 0.1 | $1.3M | 140k | 9.15 | |
Chiasma | 0.1 | $1.2M | 380k | 3.11 | |
Corvus Pharmaceuticals (CRVS) | 0.1 | $1.1M | 295k | 3.67 | |
Onconova Therapeutics | 0.1 | $894k | 423k | 2.11 | |
Arvinas Ord (ARVN) | 0.1 | $643k | 50k | 12.86 | |
Affimed Therapeutics B V | 0.1 | $492k | 158k | 3.11 | |
Constellation Pharmceticls I | 0.0 | $318k | 79k | 4.02 | |
Proqr Thrapeutics N V shs euro (PRQR) | 0.0 | $174k | 11k | 15.79 |